Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology Journal Article
| Authors: | Kumar, S. K.; Callander, N. S.; Alsina, M.; Atanackovic, D.; Biermann, J. S.; Chandler, J. C.; Costello, C.; Faiman, M.; Fung, H. C.; Gasparetto, C.; Godby, K.; Hofmeister, C.; Holmberg, L.; Holstein, S.; Huff, C. A.; Kassim, A.; Liedtke, M.; Martin, T.; Omel, J.; Raje, N.; Reu, F. J.; Singhal, S.; Somlo, G.; Stockerl-Goldstein, K.; Treon, S. P.; Weber, D.; Yahalom, J.; Shead, D. A.; Kumar, R. |
| Article Title: | Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology |
| Abstract: | Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-related complications include hypercalcemia, renal insufficiency, anemia, and infections. The NCCN Multiple Myeloma Panel members have developed guidelines for the management of patients with various plasma cell dyscrasias, including solitary plasmacytoma, smoldering myeloma, multiple myeloma, systemic light chain amyloidosis, and Waldenström's macroglobulinemia. The recommendations specific to the diagnosis and treatment of patients with newly diagnosed MM are discussed in this article. ©copy;JNCCN-Journal of the National Comprehensive Cancer Network. |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 15 |
| Issue: | 2 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2017-02-01 |
| Start Page: | 230 |
| End Page: | 269 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 28188192 |
| DOI: | 10.6004/jnccn.2017.0023 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 May 2017 -- Source: Scopus |
